Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab.
作者信息
Haddad Fadi, Daver Naval
机构信息
Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
出版信息
J Immunother Precis Oncol. 2021 May 14;4(2):67-71. doi: 10.36401/JIPO-21-X2. eCollection 2021 May.
Abstract
摘要
相似文献
1
Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab.靶向急性髓系白血病和骨髓增生异常综合征中的CD47/SIRPα：玛格罗利单抗的临床前和临床进展
J Immunother Precis Oncol. 2021 May 14;4(2):67-71. doi: 10.36401/JIPO-21-X2. eCollection 2021 May.
2
Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes.免疫检查点抑制在急性髓系白血病和骨髓增生异常综合征中的作用。
Cells. 2022 Jul 20;11(14):2249. doi: 10.3390/cells11142249.
3
Targeting the cluster of differentiation 47/signal-regulatory protein alpha axis in myeloid malignancies.靶向髓系恶性肿瘤中的分化簇47/信号调节蛋白α轴
Curr Opin Hematol. 2022 Jan 1;29(1):44-52. doi: 10.1097/MOH.0000000000000691.
4
Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives.针对恶性肿瘤中CD47/SIRPα信号通路的研究：最新进展、困难与未来展望
Front Oncol. 2024 Jul 5;14:1378647. doi: 10.3389/fonc.2024.1378647. eCollection 2024.
5
Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies.髓系恶性肿瘤中巨噬细胞免疫检查点CD47的治疗靶向作用
Front Oncol. 2020 Jan 22;9:1380. doi: 10.3389/fonc.2019.01380. eCollection 2019.
6
Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting.新型药物和方案在急性髓系白血病中的应用：2022 年美国血液学会年会最新进展。
J Hematol Oncol. 2023 Mar 3;16(1):17. doi: 10.1186/s13045-023-01411-x.
7
SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.SIRPα-αCD123 融合抗体靶向 CD123 并联合阻断 CD47 可增强 AML 起始细胞的清除。
J Hematol Oncol. 2021 Sep 27;14(1):155. doi: 10.1186/s13045-021-01163-6.
8
SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.信号调节蛋白α抗体融合蛋白刺激吞噬作用并促进急性髓系白血病细胞的清除。
Oncotarget. 2017 Feb 14;8(7):11284-11301. doi: 10.18632/oncotarget.14500.
9
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.Magrolimab 联合阿扎胞苷治疗高危骨髓增生异常综合征患者的 Ib 期研究的最终结果。
J Clin Oncol. 2023 May 20;41(15):2815-2826. doi: 10.1200/JCO.22.01794. Epub 2023 Mar 8.
10
Safety Concerns Prompt Pause of Magrolimab Trials.安全性问题促使马吉妥昔单抗临床试验暂停。
Cancer Discov. 2022 Apr 1;12(4):877-878. doi: 10.1158/2159-8290.CD-NB2022-0012.
引用本文的文献
1
Targeting Frequent Efferocytosis in Tumor Microenvironment is a New Direction for Cancer Treatment.靶向肿瘤微环境中频繁发生的吞噬作用是癌症治疗的新方向。
Small Sci. 2025 Feb 4;5(4):2400479. doi: 10.1002/smsc.202400479. eCollection 2025 Apr.
2
Advances and challenges in the treatment of myelodysplastic syndromes.骨髓增生异常综合征治疗的进展与挑战
Exp Hematol Oncol. 2025 Jun 18;14(1):87. doi: 10.1186/s40164-025-00678-9.
3
TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment.TP53突变与TET2缺陷协同作用，驱动白血病发生并建立免疫抑制环境。
J Clin Invest. 2025 Mar 20;135(10). doi: 10.1172/JCI184021. eCollection 2025 May 15.
4
Harnessing Macrophages in Cancer Therapy: from Immune Modulators to Therapeutic Targets.利用巨噬细胞进行癌症治疗：从免疫调节剂到治疗靶点。
Int J Biol Sci. 2025 Feb 26;21(5):2235-2257. doi: 10.7150/ijbs.106275. eCollection 2025.
5
Macrophages as Potential Therapeutic Targets in Acute Myeloid Leukemia.巨噬细胞作为急性髓系白血病潜在的治疗靶点
Biomedicines. 2024 Oct 11;12(10):2306. doi: 10.3390/biomedicines12102306.
6
Antibody nanoparticle conjugate-based targeted immunotherapy for non-small cell lung cancer.抗体纳米颗粒偶联物为基础的针对非小细胞肺癌的靶向免疫治疗。
Sci Adv. 2024 Jun 14;10(24):eadi2046. doi: 10.1126/sciadv.adi2046.
7
Recent Advances towards the Understanding of Secondary Acute Myeloid Leukemia Progression.对继发性急性髓系白血病进展认识的最新进展
Life (Basel). 2024 Feb 27;14(3):309. doi: 10.3390/life14030309.
8
Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies.全面表征 IFNγ 信号在急性髓系白血病中的作用揭示了预后和治疗策略。
Nat Commun. 2024 Feb 28;15(1):1821. doi: 10.1038/s41467-024-45916-6.
9
The cross-talk between macrophages and tumor cells as a target for cancer treatment.巨噬细胞与肿瘤细胞之间的相互作用作为癌症治疗的靶点。
Front Oncol. 2023 Nov 14;13:1259034. doi: 10.3389/fonc.2023.1259034. eCollection 2023.
10
Targeted Therapies in Pediatric Acute Myeloid Leukemia - Evolving Therapeutic Landscape.儿童急性髓系白血病的靶向治疗——不断变化的治疗格局。
Indian J Pediatr. 2024 Feb;91(2):176-183. doi: 10.1007/s12098-023-04741-3. Epub 2023 Jul 14.
本文引用的文献
1
Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia.1b期开放标签研究，评估阿替利珠单抗（抗PD-L1抗体）与Hu5F9-G4联合给药于复发和/或难治性急性髓系白血病患者的安全性和药代动力学。
Leuk Lymphoma. 2022 Nov;63(11):2711-2714. doi: 10.1080/10428194.2022.2092853. Epub 2022 Jul 14.
2
Current and emerging strategies for management of myelodysplastic syndromes.当前和新兴的骨髓增生异常综合征治疗策略。
Blood Rev. 2021 Jul;48:100791. doi: 10.1016/j.blre.2020.100791. Epub 2020 Dec 27.
3
New directions for emerging therapies in acute myeloid leukemia: the next chapter.新兴急性髓系白血病疗法的新方向：下一个篇章。
Blood Cancer J. 2020 Oct 30;10(10):107. doi: 10.1038/s41408-020-00376-1.
4
The Problem of TP53-Mutant MDS/AML.TP53 突变型骨髓增生异常综合征/急性髓系白血病的问题
Clin Lymphoma Myeloma Leuk. 2020 Sep;20 Suppl 1:S65-S66. doi: 10.1016/S2152-2650(20)30465-1.
5
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States.接受低甲基化药物治疗的老年急性髓系白血病患者的临床结局：美国一项基于大人群的研究
Blood Adv. 2020 May 26;4(10):2192-2201. doi: 10.1182/bloodadvances.2020001779.
6
Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies.髓系恶性肿瘤中巨噬细胞免疫检查点CD47的治疗靶向作用
Front Oncol. 2020 Jan 22;9:1380. doi: 10.3389/fonc.2019.01380. eCollection 2019.
7
Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions.急性髓细胞白血病：从突变分析到治疗决策。
Curr Hematol Malig Rep. 2019 Oct;14(5):386-394. doi: 10.1007/s11899-019-00535-7.
8
Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia.近期治疗进展以及纳米技术、组合产品和免疫疗法在改变急性髓细胞白血病治疗格局中的作用。
Pharm Res. 2019 Jun 24;36(9):125. doi: 10.1007/s11095-019-2654-z.
9
From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia.从 DNA 测序到临床试验：寻找急性髓细胞白血病的新型靶向药物。
Drugs. 2019 Jul;79(11):1177-1186. doi: 10.1007/s40265-019-01144-7.
10
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.急性髓细胞白血病，第 3.2019 版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2019 Jun 1;17(6):721-749. doi: 10.6004/jnccn.2019.0028.
Zotero 插件